The action establishes belzutifan as the only approved oral therapy for PPGL. The approval stipulates use in adults and ...

Sitting in my doctor's examination room, I was surprised when she told me,“Genetics don't really matter for chronic disease.” ...

The FDA approved belzutifan as the first oral therapy for advanced or metastatic pheochromocytoma and paraganglioma in ...

The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic ...

Durian is highly nutritious but also “hot” and calorie-dense, making it unsuitable for people with acne, pregnancy, colds, ...

About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

UNLOXCYT (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merge ...

Medical advances are changing some of the hallmark physical symptoms of sickle cell disease, columnist Oluwatosin Adesoye ...

Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in ...

Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online ...